The panel discusses the case of a 67-year-old female patient diagnosed with high-risk chronic myelomonocytic leukemia (CML-1) who presents with intermediate risk scores and abnormal blood counts, including elevated white blood cells, mild thrombocytopenia, and anemia.
This segment tackles one of the most nuanced decisions in modern myeloma treatment: determining when to use BCMA CAR T-cell therapy versus a BCMA bispecific antibody.
Panelists discuss how emerging neoadjuvant and adjuvant data in HER2-positive breast cancer are challenging traditional standards and supporting earlier use of highly effective agents.
This segment continues the discussion of high-risk MDS management, focusing on how clinicians define failure of HMAs and determine next steps in therapy, particularly in patients with TP53 mutations.
Daratumumab shows promise in managing smoldering myeloma, balancing infection risks and adverse effects while offering a preferable alternative to lenalidomide.
Experts discuss the management of immune-mediated side effects in perioperative cancer treatment, emphasizing patient care and monitoring strategies.
Ongoing studies are evaluating teclistamab-based regimens in the frontline setting as well as smoldering multiple myeloma, according to Surbhi Sidana, MD.
A potential FDA approval of teclistamab/daratumumab would offer a “highly effective” option in multiple myeloma.
Experts debate the efficacy of luspatercept versus erythropoietin in treating low-risk MDS, emphasizing individualized patient care and emerging therapies.
Experts debate the optimal timing for initiating treatment in low-risk MDS, emphasizing early intervention to enhance patient quality of life.
Panelists discuss strategies to improve access to CAR T therapy and optimize delivery across treatment settings. Key considerations include referral timing, coordination between community and academic centers, and the potential role of outpatient CAR T programs. Faculty explore how infrastructure, logistics, and multidisciplinary collaboration affect real-world access to therapy.
Next steps in surgery for gastroesophageal cancer include offerings for patients with advanced disease, such as those with oligometastases.
Panelists debate optimal second-line treatment strategies for patients with relapsed/refractory LBCL. The discussion explores decision factors such as patient fitness and lifestyle, disease biology, timing of relapse, and transplant eligibility when selecting between CAR T-cell therapy and transplant-based approaches. Faculty weigh evolving evidence alongside practical considerations influencing treatment sequencing.
Data from the GALAXY study in Japan may inform future use of total neoadjuvant therapy among patients with rectal cancer in the US.
The complicated nature of gastroesophageal cancer underscores the importance of collaboration between teams to safely treat patients with the disease.
Bodies like the NCCN must keep up with data related to ctDNA so that it can be incorporated in a measured manner, said Nicholas Hornstein, MD, PhD.
Described as a “doctor’s office on wheels,” the mobile unit is equipped with Wi-Fi and includes point-of-care PSA/imaging tests to help bring care to patients.
Explore the benefits of subcutaneous Amivantamab, including reduced infusion reactions and improved patient experience in cancer treatment.
Circulating tumor DNA may particularly help adjuvant treatment decision-making in stage II colon cancer, according to Nicholas Hornstein, MD, PhD.
The Million Strong Men Initiative is aimed at men at risk for prostate cancer who may be experiencing barriers to health care access.
Panelists discuss how results from antibody-drug conjugate trials, including those that fail primary endpoints, provide critical insights for refining sequencing strategies in hormone receptor–positive disease.
Explore the complexities of managing a Stage 3 gastric adenocarcinoma case, focusing on surgical options and perioperative treatment strategies.
This segment addresses one of the most rapidly evolving challenges in myeloma therapeutics: how to safely transition bispecific-treated patients between academic and community settings.
This case-based discussion illustrates the practical management of a 72-year-old patient with high-risk MDS and TP53 mutation.
Experts discuss the impact of daratumumab on smoldering myeloma, exploring survival rates, treatment options, and the importance of clinical trials.
Experts discuss the strengths and limitations of the Matterhorn study, highlighting advancements in immunotherapy for upper GI cancer and future research directions.
This segment focuses on the practical, multidisciplinary coordination required to safely administer bispecific antibodies.
Explore the AKELA trial's findings on patient characteristics and the impact of daratumumab on progression-free survival in myeloma treatment.
Panelists discuss how post-CDK4/6 endocrine strategies increasingly rely on molecular profiling to guide therapy selection and optimize benefit in resistant disease.
This segment explores the critical role of patient support programs, insurance navigation, and balancing the convenience of oral HMAs with ongoing clinical oversight.
